AzTrials
AzTrials

Anti-neutrophil Cytoplasmic Antibody-associated VasculitisPhase 1NCT06004947

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

A Phase 1 study testing CCX168, Midazolam and Celecoxib in people with Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis, run by Amgen at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy participants. Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
What is being tested?
CCX168, Midazolam and Celecoxib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
32 participants
Where
1 siteUnited States
Study dates
14 Jan 2016to 10 Jun 2016
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Male or female participants, aged 18-55 years inclusive, who are in generally good health as judged by the Investigator, whose body mass index is 19.0 to 32.0 kg/m^2 inclusive;
  • Willing and able to give written Informed Consent and to comply with the requirements of the study protocol;
  • Negative result of the human immunodeficiency virus screen, the hepatitis B screen, and the hepatitis C screen;
  • Judged to be healthy by the Investigator, based on medical history, physical examination (including electrocardiogram, and clinical laboratory assessments. Participants with clinical laboratory values that are outside of normal limits and/or with other abnormal clinical findings that are judged by the Investigator not to be of clinical significance may be entered into the study;
  • Female participants of childbearing potential, or male participants with partners of childbearing potential may participate if adequate contraception is used during, and for at least 90 days after, any administration of study medication.

Who cannot join

  • Pregnant or breastfeeding;
  • Used a prescription and/or over-the-counter medication, with the exception of ibuprofen, hormonal contraceptives, and multi-vitamins, within 14 days prior to check-in; herbal supplements must be stopped 7 days prior to check-in;
  • For at least 14 days prior to check-in and throughout the blood sample collection period, participants will not be allowed to eat any food or drink any beverage containing alcohol, grapefruit or grapefruit juice, apple or orange juice, vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard greens) and charbroiled meats; strenuous exercise must be stopped 4 days prior to check-in;
  • History within the three months prior to check-in of use of tobacco and/or nicotine containing products;
  • History within one year prior to check-in of illicit drug use;
  • History of alcohol abuse at any time in the past;
Show all 16Show fewer
  • Has a history or presence of any form of cancer within the 5 years prior to check-in, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis;
  • History or presence of unexplained syncope or family history of sudden death, or any medical condition or disease which, in the opinion of the Investigator, may place the participant at unacceptable risk for study participation;
  • Donated or lost more than 350 mL of blood or blood products within 56 days prior to screening, or donated plasma within 7 days of dosing;
  • Participant's hemoglobin less than 11.5 g/dL for women or less than 13.0 g/dL for men, at screening or check-in, confirmed by a repeat measurement;
  • Participated in any clinical study of an investigational product within 30 days prior to dosing or within 5 half-lives after dosing;
  • Participant has any evidence of hepatic disease; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, or bilirubin greater than 1.5 times the upper limit of normal at screening or check-in;
  • Participant's white blood cell count is below the lower limit of normal at screening or check-in, confirmed by a repeat measurement;
  • Participant has any evidence of renal impairment; serum creatinine greater than 1.5 times the upper limit of normal at screening or check-in;
  • Participant's urine tested positive at screening and/or check-in for any of the following: opioids, amphetamines and methamphetamines, cannabinoids, benzodiazepines, barbiturates, cocaine, cotinine, methylenedioxymethamphetamine (MDMA or "ecstasy"), methadone, phencyclidine, tri-cyclic antidepressants, or alcohol (Breathalyzer test allowed for alcohol).
  • Participant is known as a CYP2C9 poor metabolizer.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Celerion

    Tempe, Arizona, 85283

Other trials in United States

About this study

Official title: An Open-Label, Phase 1 Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy participants.

Being tested
CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin
Keywords
Renal diseases, Atypical hemolytic uremic syndrome, Immunoglobulin A nephropathy, Complement 5a receptor (C5aR), Complement
Medical subject headings
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Kidney Diseases, Atypical Hemolytic Uremic Syndrome, Glomerulonephritis, IGA

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CCX168Drug

    Administered orally.

  • MidazolamDrug

    Administered orally.

  • CelecoxibDrug

    Administered orally.

  • ItraconazoleDrug

    Administered orally.

  • RifampicinDrug

    Administered orally.

Study groups in NCT06004947
Study groupRoleWhat they receive
Cohort AExperimentalA single dose of 2 mg midazolam (a Cytochrome P450 [CYP]3A4 probe drug) and a single dose of 200 mg celecoxib (a CYP2C9 probe drug) will be given orally concurrently on Day 1 and Day 13. On Day 3 through Day 18, CCX168 will be given orally at 30 mg twice daily (b.i.d.), and a single dose of 30 mg CCX168 will be given in the morning on Day 19. On Day 16 through Day 19, a once daily (q.d.) dose of 200 mg itraconazole (a CYP3A4 inhibitor) will be given orally.
Receives: Drug: CCX168; Drug: Midazolam; Drug: Celecoxib; Drug: Itraconazole
Cohort BExperimentalA single dose of 30 mg CCX168 will be given on Day 1 and Day 14, while rifampicin (a CYP3A4 inducer) will be given at 600 mg once daily from Day 4 through Day 17.
Receives: Drug: CCX168; Drug: Rifampicin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cohort A: Maximum Plasma Concentration (Cmax) of Midazolam

    Measured: Up to Day 13

  2. Cohort A: Cmax of Celecoxib

    Measured: Up to Day 13

  3. Cohort A: Time of Cmax (Tmax) of Midazolam

    Measured: Up to Day 13

  4. Cohort A: Tmax of Celecoxib

    Measured: Up to Day 13

  5. Cohort A: Area under the plasma concentration-time curve (AUC) from Time 0 to infinity of Midazolam

    Measured: Up to Day 13

  6. Cohort A: AUC from Time 0 to infinity of Celecoxib

    Measured: Up to Day 13

  7. Cohort A: Apparent Terminal Half Life of Midazolam

    Measured: Up to Day 13

  8. Cohort A: Apparent Terminal Half Life of Celecoxib

    Measured: Up to Day 13

  9. Cohort A: Cmax of CCX168

    Measured: Day 15 up to Day 19

  10. Cohort A: Tmax of CCX168

    Measured: Day 15 up to Day 19

  11. Cohort A: AUC Over the Dosing Interval of CCX168

    Measured: Day 15 up to Day 19

  12. Cohort B: Cmax of CCX168

    Measured: Up to Day 14

  13. Cohort B: Tmax of CCX168

    Measured: Up to Day 14

  14. Cohort B: AUC from Time 0 to infinity of CCX168

    Measured: Up to Day 14

  15. Cohort B: Apparent Terminal Half Life of CCX168

    Measured: Up to Day 14

Secondary outcomes (3)

  1. Number of Participants Experiencing Adverse Events (AEs)

    Measured: Up to Day 29

  2. Number of Participants Experiencing Clinically Significant Changes in Laboratory Parameters

    Measured: Up to Day 19

  3. Number of Participants Experiencing Clinically Significant Changes in Vital Sign Parameters

    Measured: Up to Day 19

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Aug 2023
  2. Study start14 Jan 2016
  3. Primary completion15 Mar 2016
  4. Study completion10 Jun 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
32 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06004947
Sponsor's protocol ID
CL008_168
Status last verified
Aug 2023
First submitted
15 Aug 2023
Last updated
22 Aug 2023
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing CCX168, Midazolam and Celecoxib in people with Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis, run by Amgen at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cohort A: Maximum Plasma Concentration (Cmax) of Midazolam (time frame: Up to Day 13). The study lists 15 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06004947.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in